Kuros Aktie
18,74CHF | -1,16CHF | -5,83% |
WKN DE: A2ALS5 / ISIN: CH0325814116
Personal
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 5 | 6 | 6 | 5 | 4 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,81 | 2,30 | 3,00 | 6,71 | 18,89 |
Bilanz (in Mio. CHF) - Aktiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 34 | 33 | 31 | 27 | 45 |
Summe Anlagevermögen | 64 | 63 | 57 | 49 | 44 |
Summe Aktiva | 98 | 96 | 88 | 76 | 88 |
Bilanz (in Mio. CHF) - Passiva
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Summe Fremdkapital | 13 | 19 | 19 | 19 | 30 |
Summe Eigenkapital | 85 | 77 | 69 | 57 | 59 |
Summe Passiva | 98 | 96 | 88 | 76 | 88 |
Adresse
Wagistrasse 25, 8952 Schlieren | |
Telefon | +41 (44) 733-47-47 |
Fax | +41 (44) 733-47-40 |
Internet | http://kurosbio.com |
Management
Albert Arp
Non-Executive Director |
Christopher T. Fair
Chief Executive Officer |
Clemens A. van Blitterswijk
Chairman |
Daniel Geiger
Chief Financial Officer |
Florence Barrère de Groot
Vice President-Research & Development |
Joe Ross
Senior VP-Marketing & Business Development |
John Griffin
Chief Commercial Officer |
Joost D. de Bruijn
Executive Director & President-Innovation |
Katherine Sage
Senior Vice President-Medical & Clinical Affairs |
Luuk van Dijk
Manager-Medical & Scientific Affairs |
Marcel Borger
Head-Quality & Regulatory Affairs |
Nikki Coleman
Vice President-Global Human Resources |
Oliver Walker
Independent Non-Executive Director |
Philippe Saudan
Chief Development Officer |
Sjoerd Musters
Chief Operating Officer |